Cited by CrossRef (17)

  1. Hyeon Seok Oh, Minkyu Choi, Tae Suk Lee, Yejin An, Eun Ji Park, Tae Hwan Kim, Soyoung Shin, Beom Soo Shin. Pharmacokinetics and brain distribution of the therapeutic peptide liraglutide by a novel LC–MS/MS analysis. J Anal Sci Technol 2023;14
    https://doi.org/10.1186/s40543-023-00382-5
  2. Zi Guo. The role of glucagon-like peptide-1/GLP-1R and autophagy in diabetic cardiovascular disease. Pharmacol. Rep 2024
    https://doi.org/10.1007/s43440-024-00609-1
  3. Magdalena Cuciureanu, Cătălin-Cezar Caratașu, Levon Gabrielian, Otilia Elena Frăsinariu, Laura Elisabeta Checheriță, Laura Mihaela Trandafir, Gabriela Dumitrița Stanciu, Andrei Szilagyi, Ina Pogonea, Gabriela Bordeianu, Radu Petru Soroceanu, Călin Vasile Andrițoiu, Maria Mihalache Anghel, Diana Munteanu, Irina Teodora Cernescu, Bogdan Ionel Tamba. 360-Degree Perspectives on Obesity. Medicina 2023;59:1119
    https://doi.org/10.3390/medicina59061119
  4. Rinat Komargodski, Avigail Wittenberg, Hilla Bahat, Marianna Rachmiel. Acute Kidney and Liver Injury Associated With Low-Dose Liraglutide in an Obese Adolescent Patient. 2024;154
    https://doi.org/10.1542/peds.2023-063719
  5. Lanzhou Li, Siyu Zhai, Ruochen Wang, Fange Kong, Anhui Yang, Chunyue Wang, Han Yu, Yu Li, Di Wang. Anti-Obesity Effect of Auricularia delicate Involves Intestinal-Microbiota-Mediated Oxidative Stress Regulation in High-Fat-Diet-Fed Mice. Nutrients 2023;15:872
    https://doi.org/10.3390/nu15040872
  6. Juanjuan Zhao, Pengcheng Xu, Xiujuan Liu, Xiaobo Ji, Minjie Li, Dev Sooranna, Xiaosheng Qu, Wencong Lu, Bing Niu. Application of Machine Learning Methods for the Development of Antidiabetic Drugs. CPD 2022;28:260
    https://doi.org/10.2174/1381612827666210622104428
  7. Mavra Javed, Waqas Ahmed, Azmatullah Khan, Imtiaz Rabbani. Comparison of Efficacy of Fermented Garlic and Orlistat (Lipase Inhibitor) in Obesity Management Using an Experimental Rodent Model. Foods 2023;12:3905
    https://doi.org/10.3390/foods12213905
  8. Feras M. Almarshad, Dushad Ram. Liraglutide-Induced Depression with Suicidality in an Obese Adult: A Case Report. Galician med. j. 2024;31
    https://doi.org/10.21802/e-GMJ2024-A07
  9. Ajay Pandey, Amit Kumar Goyal. Liraglutide innovations: a comprehensive review of patents (2014–2024). Pharmaceutical Patent Analyst 2024:1
    https://doi.org/10.1080/20468954.2024.2366693
  10. Kamlesh K. Bhopale, Mukund P. Srinivasan. Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). Livers 2023;3:597
    https://doi.org/10.3390/livers3040040
  11. Mariana Cornelia Tilinca, Robert Aurelian Tiuca, Alexandru Burlacu, Andreea Varga. A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review. Medicina 2021;57:669
    https://doi.org/10.3390/medicina57070669
  12. Shichao Dong, Chuan Sun. Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data. Front. Endocrinol. 2022;13
    https://doi.org/10.3389/fendo.2022.1032199
  13. Juyoung Shin, Raeun Kim, Hun-Sung Kim. Liraglutide, a glucagon-like peptide-1 analog, in individuals with obesity in clinical practice. CPP 2023;5:49
    https://doi.org/10.36011/cpp.2023.5.e7
  14. Rui-Chian Tang, I-Hsuan Yang, Feng-Huei Lin. Current Role and Potential of Polymeric Biomaterials in Clinical Obesity Treatment. Biomacromolecules 2023;24:3438
    https://doi.org/10.1021/acs.biomac.3c00388
  15. Vikash Pandey, Patil A. Adhikrao, Gudle M. Motiram, Nisha Yadav, Utkarsh Jagtap, Gautam Kumar, Atish Paul. Biaryl carboxamide‐based peptidomimetics analogs as potential pancreatic lipase inhibitors for treating obesity. Archiv der Pharmazie 2024;357
    https://doi.org/10.1002/ardp.202300503
  16. Lamija Ferhatbegović, Denis Mršić, Amra Macić-Džanković. The benefits of GLP1 receptors in cardiovascular diseases. Front. Clin. Diabetes Healthc. 2023;4
    https://doi.org/10.3389/fcdhc.2023.1293926
  17. Iu.G. Samoilova, A.E. Stankova, M.V. Matveeva, O.E. Vaizova, D.V. Podchinenova, D.A. Kudlay, T.A. Filippova, I.R. Grishkevich. Pharmacogenetics of glucagon-like peptide-1 agonists in the treatment of type 2 diabetes mellitus. Profil. med. 2023;26:95
    https://doi.org/10.17116/profmed20232612195